SCHEMBL6613845

SCHEMBL6613845

O=S(=O)(Nc1cscc1-c1sccc1Cl)c1ccc(Cl)c(Cl)c1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 2/20 0.44
MAPT P10636 2/20 0.44
CYP1A2 P05177 1/20 0.44
POLB P06746 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
RECQL P46063 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
HSD11B1 P28845 1/20 0.38
ESR2 Q92731 1/20 0.36
HSD17B10 Q99714 1/20 0.36
PTGES2 Q9H7Z7 5/20 0.36
PFKFB3 Q16875 1/20 0.35
SLC40A1 Q9NP59 1/20 0.35
PKM P14618 1/20 0.35
MCL1 Q07820 3/20 0.34
HPGD P15428 1/20 0.33
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6694589 0.84 USP2 (0.63) USP2MAPTCYP1A2POLBCYP3A4
SCHEMBL6616101 0.84 USP2 (0.47) USP2MAPTCYP1A2POLBCYP3A4
SCHEMBL6613199 0.83 USP2 (0.43) USP2MAPTCYP1A2POLBCYP3A4
SCHEMBL6610699 0.80 SLC40A1 (0.49) USP2MAPTCYP1A2POLBCYP3A4
SCHEMBL6612018 0.80 SLC40A1 (0.44) USP2MAPTCYP1A2POLBCYP3A4
SCHEMBL6609567 0.80 PTGES2 (0.46) POLBPTGES2PFKFB3SLC40A1PKM
SCHEMBL6615207 0.79 MAPT (0.45) USP2MAPTCYP1A2POLBCYP3A4
SCHEMBL6609438 0.77 HSD11B1 (0.66) USP2MAPTCYP1A2POLBCYP3A4
SCHEMBL2762552 0.77 POLB (0.73) USP2MAPTCYP1A2POLBCYP3A4
SCHEMBL6614439 0.76 PTGES2 (0.45) MAPTPOLBPTGES2PFKFB3SLC40A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004112779-A1 NEW USE VII BIOVITRUM AB (SE) 2004-12-29 WO claimed
EP-1461333-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 EP claimed
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 US claimed
WO-2003044009-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 WO claimed
WO-2004112779-A1 NEW USE VII BIOVITRUM AB (SE) 2004-12-29 WO disclosed
EP-1461333-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 EP disclosed
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 US disclosed
WO-2003044009-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD3B1 USP2 2740/4885MAPT 3254/4885CYP1A2 74/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.